Subjective and Objective Measurements of the Facial Effects of Microdoses of Botulinum Toxin
Keywords:
botulinum toxin, microdoses, skin quality, erythema, telangiectasiasAbstract
Introduction: Studies have suggested that botulinum toxin A may improve skin quality, and application protocols using hyper-diluted doses of botulinum toxin (microdosing) have been studied as a way to achieve therapeutic goals without fully paralyzing the targeted muscles.
Objectives: To evaluate the effects of a combined protocol utilizing both the standard dosing and the microdosing of AbobotulinumtoxinA for the improvement of skin quality, measured by objective and subjective measurements.
Methods: Thirty patients were treated with botulinum toxin using both the standard technique and the microdosing technique. Objective (Sebumeter®, Mexameter® and digital dermoscopy pictures) and subjective (Global Aesthetic Improvement Scale and a clinical scale for evaluating the quality of facial skin) measurements of the effects in the treated areas were taken to assess the efficacy of the treatment.
Results: Digital dermoscopy showed a marked reduction of erythema and telangiectasias. Erythema and telangiectasias improved both on objective and subjective measurements. Skin oleosity, static rhytids, papules and pustules and enlarged pores improved on subjective measurements. Patient satisfaction was high (93%) despite the high rate of adverse events (56%).
Conclusions: The combined application of standard doses and microdoses of AbobotulinumtoxinA is effective in improving the overall quality of facial skin. The effects on erythema and telangiectasias suggest that it is an effective treatment option for patients with erythematotelangiectatic rosacea. When applying microdoses of botulinum toxin in the lower and mid-face, the doses and pattern of injection should be customized for each patient to reduce the occurrence of adverse events.
References
Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. Adv Dermatol. 1997;12:325-47; discussion 348. PMID: 8973746.
Hexsel D, Brum C, Porto MD, Soirefmann M, et al. Full-face injections of variable total doses of abobotulinum toxin type a: a randomized, phase iv clinical trial of safety and efficacy. J Drugs Dermatol. 2013;12(12):1356-1362. PMID: 24301236.
Hexsel D, Dal'Forno T, Hexsel C, OliveiraCamozzato F. Long-Term Cumulative Effects of Repeated Botulinum Toxin Type A Injections on Brow Position. Dermatol Surg. 2020;46(9):1252-1254. DOI: 10.1097/DSS.0000000000002142. PMID: 31517662.
Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. Toxins (Basel). 2021;13(2):120. DOI: 10.3390/toxins13020120. PMID: 33562846. PMCID: PMC7915854.
Shirshakova M, Morozova E, Sokolova D, Pervykh S, Smirnova L. The effectiveness of botulinum toxin type A (BTX-A) in the treatment of facial skin oily seborrhea, enlarged pores, and symptom complex of post-acne. Int J Dermatol. 2021;60(10):1232-1241. DOI: 10.1111/ijd.15574. PMID: 33937981.
Zhang H, Tang K, Wang Y, Fang R, Sun Q. Use of Botulinum Toxin in Treating Rosacea: A Systematic Review. Clin Cosmet Investig Dermatol. 2021;14:407-417. DOI: 10.2147/CCID.S307013. PMID: 33958886. PMCID: PMC8096341.
Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part II: Wrinkles on the middle and lower face, neck and chest. J Eur Acad Dermatol Venereol. 2010;24(11):1285-1295. DOI: 10.1111/j.1468-3083.2010.03728.x. PMID: 20569284.
Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) – part I: upper facial wrinkles. J Eur Acad Dermatol Venereol. 2010;24(11):1278-1284. DOI: 10.1111/j.1468-3083.2010.03631.x. PMID: 20337830.
Steinsapir KD, Rootman D, Wulc A, Hwang C. Cosmetic Microdroplet Botulinum Toxin A Forehead Lift: A New Treatment Paradigm. Ophthalmic Plast Reconstr Surg. 2015;31(4):263-268. DOI: 10.1097/IOP.0000000000000282. PMID: 25216199.
Kim MJ, Kim JH, Cheon HI, et al. Assessment of Skin Physiology Change and Safety After Intradermal Injections With Botulinum Toxin: A Randomized, Double-Blind, Placebo-Controlled, Split-Face Pilot Study in Rosacea Patients With Facial Erythema. Dermatol Surg. 2019;45(9):1155-1162. DOI: 10.1097/DSS.0000000000001819. PMID: 30730346.
Gangigatti R, Bennani V, Aarts J, Choi J, Brunton P. Efficacy and safety of Botulinum toxin A for improving esthetics in facial complex: A systematic review. Braz Dent J. 2021;32(4):31-44. DOI: 10.1590/0103-6440202104127. PMID: 34787249.
Husein-ElAhmed H, Steinhoff M. Light-based therapies in the management of rosacea: a systematic review with meta-analysis. Int J Dermatol. 2022;61(2):216-225. DOI: 10.1111/ijd.15680. PMID: 34089264.
Oliveira CMM, Almeida LMC, Bonamigo RR, Lima CWG, Bagatin E. Consensus on the therapeutic management of rosacea - Brazilian Society of Dermatology. An Bras Dermatol. 2020;95 Suppl 1(Suppl 1):53-69. DOI: 10.1016/j.abd.2020.08.001. PMID: 33172727. PMCID: PMC7772594.
Scala J, Vojvodic A, Vojvodic P, et al. Botulin Toxin Use in Rosacea and Facial Flushing Treatment. Open Access Maced J Med Sci. 2019;7(18):2985-2987. DOI: 10.3889/oamjms.2019.784. PMID: 31850105. PMCID: PMC6910814.
Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93(1):58-64. DOI: 10.1016/j.jdermsci.2018.12.004. PMID: 30658871. PMCID: PMC7680644.
Shamloul G, Khachemoune A. An updated review of the sebaceous gland and its role in health and diseases Part 1: Embryology, evolution, structure, and function of sebaceous glands. Dermatol Ther. 2021;34(1):e14695. DOI: 10.1111/dth.14695. PMID: 33354858.
Published
Issue
Section
License
Copyright (c) 2023 Doris Hexsel, Indira Valente-Bezerra, Gabriela Mosena, Maria Antonia Oakim Mourao, Vitor Costa Fabris
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
